Could Value-Based Pricing Be Yet Another Roadblock To Biosimilar Uptake?

As pay-for-performance drugs becomes more high-profile in the U.S., these emerging deals pose a number of difficulties for reference makers. But if pay-for-performance becomes more wide-spread, could innovators' successes become yet another roadblock to getting biosimilars into doctor's treatment repertoire and patients' hands?

Source: Pharmaceutical Online News - March 3, 2016 Category: Pharmaceuticals Source Type: news